The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

Kristin Brekke, Maja Sommerfelt, Mats Ökvist, Anne Margarita Dyrhol-Riise, Dag Kvale

Open source

DOI
10.1186/s12879-017-2316-x
Published
2017-03-24
Container
BMC Infectious Diseases
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12879-017-2316-x,
  title = {The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study},
  author = {Kristin Brekke and Maja Sommerfelt and Mats Ökvist and Anne Margarita Dyrhol-Riise and Dag Kvale},
  year = {2017},
  journal = {BMC Infectious Diseases},
  doi = {10.1186/s12879-017-2316-x},
  url = {https://doi.org/10.1186/s12879-017-2316-x}
}

RIS

TY  - JOUR
TI  - The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study
AU  - Kristin Brekke
AU  - Maja Sommerfelt
AU  - Mats Ökvist
AU  - Anne Margarita Dyrhol-Riise
AU  - Dag Kvale
PY  - 2017
JO  - BMC Infectious Diseases
DO  - 10.1186/s12879-017-2316-x
UR  - https://doi.org/10.1186/s12879-017-2316-x
ER  - 

APA

Brekke, K., Sommerfelt, M., Ökvist, M., Dyrhol-Riise, A. M., & Kvale, D. (2017). The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-017-2316-x

Source records